Anzemet
(Dolasetron)Phase 3Small molecule
Dolasetron is used to prevent nausea and vomiting that occurs as a side effect of cancer chemotherapy. It works by blocking serotonin in the body, which is responsible for triggering these uncomfortable symptoms.[1] Anzemet is currently being investigated across 2 indications[3], with its most advanced program in Phase 3.[1]
Anzemet is one of 65 small molecule programs targeting Chemotherapy-induced nausea and vomiting. It is currently in Phase 3.
2
Indications
3
Total Trials
1
Active Trials
64
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
152 competitors in Fibromyalgia
#DrugCompanyPhaseTrials
1Xyrem
Jazz PharmaceuticalsPhase 3
Epidiolex
Jazz PharmaceuticalsPhase 3
Namenda
AbbViePhase 3
Neurontin
VViatris Specialty LLC
Phase 3
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Ultram
WWim Janssens
Phase 3
DS-5565
Daiichi SankyoPhase 3
Feosol
AAuerbach Hematology Oncology Associates P C
Phase 3
Genotropin
EMD SeronoPhase 3
Saizen
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chemotherapy-induced nausea and vomiting1 trial
Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT06593782·180 enrolled
Regulatory
FDA Approval Timeline[4]
Sep 11, 1997
ANZEMET
NDA NDA020624
Sep 11, 1997
ANZEMET
NDA NDA020623
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dolasetron. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- VValidus Pharmaceuticals